PAIN MANAGEMENT THERAPEUTICS MARKET ANALYSIS

Pain Management Therapeutics Market, By Pain Type (Chronic, Acute), By Drug Class (NSAIDS, Anesthetics, Anticonvulsant, Anti-migraine Drugs, Antidepressant Drugs, Opioids, Non-narcotics, Analgesics), By Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, Others) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Sep 2021
Code : CMI4626
Pages :243
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa

North America held dominant position in the global pain management therapeutics market in 2020, accounting for 32.40% share in terms of volume, followed by Europe and Asia Pacific, respectively. Companies operating in North America are extensively engaged in R&D activities for developing new pain management drugs which can be attributed to the dominant position of the region in the market. For instance, January 2021, Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company recently completed Phase 2 clinical trial of vocacapsaicin (CA-008), a first-in-class, non-opioid therapeutic with FDA Breakthrough Therapy Designation.

Pain Management Therapeutics Market Report Snapshots